Objective To investigate the value of ultrasound functional imaging in evaluation of the curative effect in patients with cervical cancer undergoing concurrent chemoradiotherapy. Methods A total of 41 patients with cervical cancer who admitted to the hospital from January 2017 to February 2018 were enrolled into the study. All patients were treated with concurrent chemoradiotherapy. Ultrasound functional imagingand the elastic strain ratio was used to detect the lesions before treatment, 1 week and 2 weeks after treatment and at the end of treatment. The curative effect of concurrent chemoradiotherapy was analyzed. Results A total of 26 patients (63.41%) had complete remission (CR) and 15 patients (36.59%) had partial remission (PR) after concurrent chemoradiotherapy. The cervical morphology recovered significantly, the lesions decreased or disappeared, and the cervical line was continuous and visible after treatment. The maximum long diameter in CR group before treatment was (38.64±7.57) mm and lesions disappeared completely after treatment. The maximum long diameter in PR group was significantly decreased after treatment [(42.07±8.39) mm vs (23.94±6.31) mm] (P<0.01). The elastic imaging results of CR group were green overall after treatment and in PR group, the central part of the lesion was mainly green, with some focal blue areas. As the treatment progressed, the elastic strain ratio of lesions showed a downward trend. The elastic strain ratio in CR group decreased significantly 1 week after treatment (P<0.05), while the elastic strain ratio in PR group decreased significantly at 2 weeks after treatment (P<0.05). The elastic strain ratios of CR group were lower than those of PR group at 1 week and 2 weeks after treatment and at the end of treatment (P<0.05). Conclusion Ultrasound functional imaging can accurately reflect the effects of concurrent chemoradiotherapy on cervical cancer by early continuous monitoring of elastic strain ratio, and it is of predictive value for evaluating the curative effect on cervical cancer.